Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
19 12월 2023 - 10:00PM
Edgar (US Regulatory)
FORM
6-K
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
dated
December 19, 2023
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
December 19, 2023
|
GENETIC TECHNOLOGIES LIMITED |
|
|
|
By: |
/s/
Tony Di Pietro |
|
Name: |
Tony Di Pietro |
|
Title: |
Company Secretary |
EXHIBIT
INDEX
Exhibit
99.1
ASX
Market Announcement |
|
Receipt
of R&D Tax Incentive Refund
Melbourne,
Australia, 18 December 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global
leader in genomics-based tests in health, wellness and serious disease, is pleased to advise that the Company has received $1.75m from
the federal government’s Research and Development (R&D) Tax Incentive program for the 2023 financial year.
The
amount received represents 43.5% of the Company’s eligible R&D expenditure for the 2023 financial year.
-END-
Authorised
for release by the board of directors of Genetic Technologies Limited.
Enquiries
Investor
Relations
Adrian
Mulcahy
Automic
Markets
M:
+61 438 630 411
E:
adrian.mulcahy@automicgroup.com.au
About
Genetic Technologies Limited
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests
in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment
tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform
that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and
individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues
to develop risk assessment products. For more information, please visit www.genetype.com
Genetic
Technologies Limited
www.genetype.com
info@gtglabs.com
ABN
17 009 212 328 |
60-66
Hanover Street
Fitzroy
Victoria 3065
Australia
+61
3 8412 7000 |
|
Genetic Technologies (PK) (USOTC:GNTLF)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Genetic Technologies (PK) (USOTC:GNTLF)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025